Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib vs Apatinib + Camrelizumab in Advanced Gastric Cancer
NCT05095636Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 36 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05095636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095636.